American Well Corporation reports its Q1 2026 results today with options traders making an abrupt pivot away from the defensive stance that defined the past month.
The shift in options positioning is the sharpest signal heading into the print. The put/call ratio has collapsed to 0.41 — nearly three standard deviations below its 20-day average of 1.65 — flipping from well above-average bearishness to the most call-heavy reading of the past several months. That is a dramatic intraday reversal from 1.16 just one session earlier. The wider borrow market tells a quieter story: short interest is a modest 2.1% of the free float and has edged up roughly 14% over the past month, but availability remains abundant and borrowing costs are negligible at 0.60% — nothing in the lending data points to meaningful short-seller conviction.
The stock has done most of its work already. AMWL is up 16% over the past month and 31% year-to-date, closing at $6.36. That move was partly anchored to the Q4 print in February, which delivered a one-day gain of 25% and a five-day follow-through of 33% — the largest single-day reaction in recent history. The question heading into today's release is whether that momentum has set an uncomfortable bar. Closest US peer gained 11% on the week; added 5% and climbed 10%, suggesting a broadly supportive sector backdrop rather than AMWL-specific positioning.
The bull case centres on subscription-revenue momentum — specifically the Digital Health Applications segment, which grew 29% year-over-year in Q4 — and the company's track record of beating adjusted EBITDA guidance. Bears point to aggressive cost cutting in G&A and sales and marketing that raises questions about whether revenue generation can hold up as the company trims the muscle alongside the fat. Analyst sentiment has been cautiously negative over the past year: targets have been lowered by multiple firms, and the mean sits at $7.00 against the current price of $6.36 — implying limited upside from the Street's current pencilling. The most recent move from Stifel, which cut its target to $5.00 following the February print, remains the last published action and is dated enough to treat as background rather than live guidance. EPS momentum ranks in the bottom quintile of the universe over both 30- and 90-day windows, a reminder that forward estimates have been drifting lower even as the stock recovered.
Today's print is therefore less about the headline EBITDA number and more about whether subscription revenue can accelerate into H2 2026 at a rate that justifies the stock's near-doubling off last year's lows.
See the live data behind this article on ORTEX.
Open AMWL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
